Trevi Therapeutics’ (TRVI) “Buy” Rating Reiterated at D. Boral Capital

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They presently have a $19.00 price objective on the stock. D. Boral Capital’s price objective suggests a potential upside of 58.40% from the company’s previous close.

A number of other research firms have also commented on TRVI. Leerink Partners increased their price target on Trevi Therapeutics from $13.00 to $16.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research note on Monday. Morgan Stanley raised their target price on Trevi Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Friday, November 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Wednesday, January 21st. Finally, Oppenheimer raised their price objective on shares of Trevi Therapeutics from $23.00 to $24.00 and gave the company an “outperform” rating in a research report on Friday, November 14th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $21.10.

Trevi Therapeutics Price Performance

Shares of TRVI traded down $1.31 during trading hours on Monday, hitting $12.00. The stock had a trading volume of 1,417,302 shares, compared to its average volume of 1,414,110. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of -32.42 and a beta of 0.94. The company’s fifty day moving average is $11.26 and its two-hundred day moving average is $10.73. Trevi Therapeutics has a 52 week low of $4.85 and a 52 week high of $14.39.

Institutional Trading of Trevi Therapeutics

A number of institutional investors have recently bought and sold shares of TRVI. Rubric Capital Management LP raised its position in shares of Trevi Therapeutics by 88.0% during the 2nd quarter. Rubric Capital Management LP now owns 8,531,860 shares of the company’s stock valued at $46,669,000 after acquiring an additional 3,993,325 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Trevi Therapeutics by 10.4% during the fourth quarter. Vanguard Group Inc. now owns 6,434,655 shares of the company’s stock worth $80,562,000 after buying an additional 607,669 shares during the last quarter. Viking Global Investors LP boosted its holdings in Trevi Therapeutics by 232.4% during the third quarter. Viking Global Investors LP now owns 5,128,875 shares of the company’s stock worth $46,929,000 after buying an additional 3,585,875 shares during the last quarter. Vivo Capital LLC grew its position in shares of Trevi Therapeutics by 13.5% during the 3rd quarter. Vivo Capital LLC now owns 5,094,668 shares of the company’s stock worth $46,616,000 after buying an additional 606,765 shares during the period. Finally, Marshall Wace LLP increased its stake in shares of Trevi Therapeutics by 95.4% in the 3rd quarter. Marshall Wace LLP now owns 4,841,751 shares of the company’s stock valued at $44,302,000 after acquiring an additional 2,363,835 shares during the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.